Navigation Links
Pacira Pharmaceuticals Names David M. Stack CEO and President
Date:12/18/2007

Stack served as the President and General Manager of Innovex, Inc. and was responsible for the Americas. Innovex, Inc. is a commercial solutions company offering a full range of marketing, sales and clinical development capabilities to pharmaceutical and biotechnology customers.

Mr. Stack's prior experience also includes serving as the Vice President of Business Development and Marketing for Immunomedics, Inc. (Nasdaq: IMMU), as well as multiple senior business management positions at Roche Labs. Before he entered the commercial pharmaceutical sector, Mr. Stack was a retail and hospital pharmacist for three years after graduating from Albany College of Pharmacy. He also holds a BS in Biology from Siena College. Dave was recognized as the Ernst and Young Entrepreneur of the Year in 2003 (New Jersey Healthcare). He is a Director of Bio-Imaging Technologies, Inc. (Nasdaq: BITI), Medsite, Inc., PepTx, Inc. and QRxPharma Pty Ltd.

About Pacira Pharmaceuticals, Inc.

Pacira Pharmaceuticals, Inc. is a wholly owned subsidiary of Pacira Inc., a Delaware corporation, which is controlled and funded by a group of financial investors including HBM BioVentures (Cayman) Ltd., MPM Capital, OrbiMed Advisors, and Sanderling Ventures. This business is based in San Diego, CA, and formulates, develops and manufactures controlled-release injectable products based on two proprietary drug delivery platforms: DepoFoam(R) and Biosphere(R). Revenues are generated from two marketed products: DepoCyt(R) for lymphomatous meningitis and
'/>"/>

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Flynn Pharma Acquires Rights From Pacira Pharmaceuticals to DepoDur(R), the Only Extended-Release Epidural Opioid for Post-Operative Pain, in Europe
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 17, 2015 Wholelifelifeinsurance.org has released ... whole life insurance policies . , Whole ... financial security for their families at the same time. ... options which can be customized to it the client’s ... reduced if clients take some appropriate steps.Comparing life insurance ...
(Date:4/17/2015)... Verndale, a Global Experience Technology Company, is pleased ... as a Boston Business Journal (BBJ) Pacesetter, ranking as ... The BBJ’s Pacesetters represents privately held businesses that recorded ... is the eighth consecutive year and the ninth time ... honored with this award. , “Being honored with this ...
(Date:4/17/2015)... 17, 2015 Cheapquotesautoinsurance.com has released a new ... has a salvage title . , An auto insurance ... a salvage title if the owner has paid for all ... title car is not possible, while in other states, the ... blog post provides more information on the subject. , ...
(Date:4/17/2015)... 17, 2015 Founder of the ... as a keynote speaker at the Couples Conference from ... Marriott in Manhattan Beach, CA. Tatkin’s presentation and panel ... can help couples become “secure-functioning” – a term he ... of research in neurobiology, arousal regulation, and infant attachment ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 The American ... that Long Island eye surgeon Jeffrey L. Martin, will ... Cataract Surgery Skills Transfer Session being held April 17-21 ... Martin is the Managing Partner of North Shore Eye ... fellow ophthalmologists attending the Skills Transfer Session in learning ...
Breaking Medicine News(10 mins):Health News:Whole Life Insurance Policies At Affordable Prices By Comparing Quotes 2Health News:Verndale Honored as 2015 Boston Business Journal Pacesetter, Named 46th Fastest Growing Private Company 2Health News:Compare Auto Insurance Quotes for Cars With A Salvage Title! 2Health News:Best-Selling Author, Therapist and Founder of the PACT Institute Will Give a Keynote Address at 2015 Couples Conference 2Health News:Best-Selling Author, Therapist and Founder of the PACT Institute Will Give a Keynote Address at 2015 Couples Conference 3Health News:American Society of Cataract & Refractive Surgery Selects Dr. Jeffrey Martin To Serve As Lead Instructor For Laser Cataract Surgery Skills Transfer Session 2Health News:American Society of Cataract & Refractive Surgery Selects Dr. Jeffrey Martin To Serve As Lead Instructor For Laser Cataract Surgery Skills Transfer Session 3
... important regulatory enzyme may slow the loss of brain ... disorders. In a report receiving advance online publication ... (MGH)-based research team reports that increased expression of Sirt1, ... the brain of a mouse model of HD protected ...
... a dentist but not a general healthcare provider, according to an ... Health . The study, conducted by a nursing-dental research team ... proportion of Americans who are seen annually by a dentist but ... suggests dentists can play a crucial role as health care practitioners ...
... Reporter , FRIDAY, Dec. 16 (HealthDay News) -- Not only does ... in their quality of life, new research finds. ... are a lot of benefits that you might not have thought ... you,d have more stress, that quitting would put more stress on ...
... for the treatment of breast cancer has been ... the U.S. as an alternative to standard whole-breast ... 16th in the Journal of the ... APBI recurrence (external beam radiation, intraoperative radiotherapy, brachytherapy ...
... , FRIDAY, Dec. 16 (HealthDay News) -- First responders ... than double the rate of the general U.S. population, new ... 8 in the American Journal of Industrial Medicine , ... the result of their exposure to the toxic dust created ...
... Road Rippers Lightning Rods, Let,s Rock Elmo and the I ... season, parents should ensure that their children don,t risk permanent ... Department of Otolaryngology measured the noise levels of two dozen ... precise gauging in a soundproof booth at UC Irvine Medical ...
Cached Medicine News:Health News:Regulatory enzyme overexpression may protect against neurodegeneration in Huntington's disease 2Health News:NYU study concludes that dentists could screen 20 million Americans for chronic physical illnesses 2Health News:Life After Cigarettes Is Happier: Study 2Health News:Life After Cigarettes Is Happier: Study 3Health News:Advantages and motivations uncertain behind use of brachytherapy for breast cancer radiotherapy 2Health News:Advantages and motivations uncertain behind use of brachytherapy for breast cancer radiotherapy 3Health News:WTC First Responders More Likely to Have Asthma: Study 2Health News:UC Irvine researchers urge caution when buying noisy toys 2
(Date:4/17/2015)... DUBLIN , Apr. 17, 2015 Research ... announced the addition of the "Medical Device ... to their offering. This report analyzes ... US$ Million by the following Device Categories: Class ... areas also analyzed in the report Include - ...
(Date:4/17/2015)... 17, 2015  Trovagene, Inc., (NASDAQ:  TROV) a ... clinical data presented at the 2015 European Lung ... Cancer Monitoring ℠ (PCM) platform outperformed tissue ... EGFR T790M mutations in metastatic lung cancer ... T790M Mutation in Urinary Circulating Tumor DNA from ...
(Date:4/17/2015)... 2015 Steven Rash , the CEO of ... operating subsidiary American Seed & Oil Company, presented the ... yesterday in New York City.  Mr. Rash,s presentation featured ... Seed & Oil Company has recently announced the ... Seed Foods , the EpiVape , and ...
Breaking Medicine Technology:Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 2Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 4American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 2American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 3
... Silence Therapeutics plc (AIM: SLN) ("Silence" or ... patent 7,893,245, titled "Interfering RNA Molecules," by the ... issued patent, which represents a continuation of previously ... RNAi molecules with defined positional modifications including siRNA ...
... Feb. 22, 2011 Covance Inc. (NYSE: CVD ... Annual Morningstar/NYSSA Healthcare Conference on Thursday, February 24, 2011 at ... the presentation at www.covance.com .  In order to register ... early. Covance, with headquarters in Princeton, New Jersey, ...
Cached Medicine Technology:Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials 2Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials 3Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials 4Covance to Present at the 2nd Annual Morningstar/NYSSA Healthcare Conference 2
Total IgE Control...
The K-ASSAY Lp(a) Control Set is intended for use as an assayed quality control material for monitoring the performance of Lp(a) immunoturbidimetric assays....
... The K-ASSAY ASO / ... is intended to be used ... of known concentration for monitoring ... O (ASO), Rheumatoid Factor (RF), ...
Eppendorf expands its line of benchtop microcentrifuges with the 5418. This easy-to-use microcentrifuge features a certified aerosol-tight rotor and a unique, contoured rotor bowl design to reduce no...
Medicine Products: